T1	Participants 0 137	Sorafenib dose escalation is not uniformly associated with blood pressure elevations in normotensive patients with advanced malignancies.
T2	Participants 286 310	advanced cancer patients
T3	Participants 1131 1217	Patients have intrinsic differences in sensitivity to sorafenib's BP-elevating effects
T4	Participants 1039 1130	normotensive patients suggest BP is a complex pharmacodynamic biomarker of VEGF inhibition.
